CTNM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
17.4M
+3.1%
16.9M
-1.2%
17.1M
+14.6%
14.9M
-16.6%
17.9M
R&D
12.7M
+9.0%
11.6M
-8.7%
12.8M
+16.0%
11.0M
-21.8%
14.1M
SG&A
4.7M
-10.1%
5.3M
+20.6%
4.4M
+10.7%
3.9M
+2.6%
3.8M
Operating Income
-17428000
-3.1%
-16904000
+1.2%
-17115000
-14.6%
-14932000
+16.6%
-17902000
EBITDA
-17294000
-2.8%
-16821000
+1.2%
-17030000
-14.7%
-14851000
+16.7%
-17823000
Net Income
-15154000
-4.8%
-14456000
+4.6%
-15156000
-18.5%
-12792000
+20.2%
-16040000
EPS (Basic)
$-0.40
-2.6%
$-0.39
+20.4%
$-0.49
-8.9%
$-0.45
+27.4%
$-0.62
EPS (Diluted)
$-0.40
-2.6%
$-0.39
+20.4%
$-0.49
-8.9%
$-0.45
+27.4%
$-0.62
Shares (Diluted)
37.5M
+0.3%
37.3M
+20.7%
30.9M
+10.0%
28.1M
+8.6%
25.9M
Contineum Therapeutics (CTNM) โ€” Financials